+278.4%
TER vs MRNA
+27.9%
+250.5%
-58.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.5% | +0.7% | -4.3% | -3.5% |
| 7D | +9.4% | -8.2% | +17.6% | +9.7% |
| 30D | -2.4% | +125.6% | -128.0% | -10.8% |
| 3M | +6.5% | +197.1% | -190.5% | -11.6% |
| 6M | +23.2% | +148.5% | -125.3% | +6.9% |
| YTD | +91.5% | +363.3% | -271.8% | +39.4% |
| 1Y | +214.8% | +462.0% | -247.2% | +115.2% |
| All | +278.4% | +27.9% | +250.5% | +220.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling